Advertisement

PharmacoEconomics

, Volume 35, Issue 12, pp 1223–1236 | Cite as

Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence

  • Jan NorumEmail author
  • Carsten Nieder
Review Article

Abstract

Background

Prostate cancer (PC) is the most common cancer in Western countries. More than one third of PC patients develop metastatic disease, and the 5-year expected survival in distant disease is about 35%. During the last few years, new treatments have been launched for metastatic castrate-resistant prostate cancer (mCRPC).

Objectives

We aimed to review the current literature on health economic analysis on the treatment of metastatic prostate cancer (mPC), compare the studies, summarize the findings and make the results available to administrators and decision makers.

Methods

A systematic literature search was done for economic evaluations (cost-minimization, cost-effectiveness, cost-utility, cost-of-illness, cost-of-drug, and cost-benefit analyses). We employed the PubMed® search engine and searched for publications published between 2012 and 2016. The terms used were “prostate cancer”, “metastatic” and “cost”. An initial screening of all headlines was performed, selected abstracts were analysed, and finally the full papers investigated. Study characteristics, treatment and comparator, country, type of evaluation, perspective, year of value, time horizon, efficacy data, discount rate, total costs and sensitivity analysis were analysed. The quality was assessed using the Quality of Health Economic Studies (QHES) instrument.

Results

A total of 227 publications were detected and screened, 58 selected for full-text assessment and 31 included in the final analyses. Despite the significant international literature on the treatment of mCRPC, there were only 15 studies focusing on cost-effectiveness analysis (CEA). Medical treatment constituted two thirds of the selected studies. Significant costs in the treatment of mCRPC were disclosed. In the pre-docetaxel setting, both abiraterone acetate (AA) and enzalutamide were concluded beyond accepted cost/quality-adjusted life year limits. In the docetaxel refractory setting, most studies concluded that enzalutamide was cost-effective and superior to AA. In most studies, cabazitaxel was not recommended, because of high cost. Looking at bone-targeting drugs, generic zoledronic acid (ZA) was recommended. External beam radiotherapy (EBRT) was analysed in three studies, and single fraction radiotherapy was concluded to be cost saving. Radium-223 was documented as beneficial, but costly. The quality of the studies was generally good, but sensitivity analyses, discounting and the measurement of health outcomes were present in less than two thirds of the selected studies.

Conclusions

The treatment of mCRPC was associated with significant cost. In the post-docetaxel setting, single fraction radiotherapy and enzalutamide were considered cost-effective in most studies. Generic ZA was the recommended bone-targeting therapy.

Notes

Acknowledgements

The authors acknowledge the service offered by the library at the Faculty of Health Science at the UiT—The Arctic University of Norway, which made all articles available to the researchers. We are also grateful to the librarian at the Nordland Hospital Bodø.

Author Contributions

The editor of PharmacoEconomics suggested the review. Both authors developed the idea. JN did the search employing the PubMed® search engine and screened all articles and performed all full-text analyses. The writing process was done by CN and JN.

Compliance with Ethical Standards

Conflict of interest

Jan Norum and Carsten Nieder declare they have no conflicts of interest relevant to the content of this article.

Supplementary material

40273_2017_555_MOESM1_ESM.docx (100 kb)
Supplementary material 1 (DOCX 100 kb)

References

  1. 1.
    Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV, et al. Prostate cancer, version 1.2014. National Comprehensive Cancer Network. J Natl Compr Cancer Netw. 2013;11(12):1471–9.CrossRefGoogle Scholar
  2. 2.
    Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32(30):3436–48.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011;105(11):1795–803.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Cancer Registry of Norway. Cancer in Norway 2015. Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2016.Google Scholar
  5. 5.
    Seal BS, Asche CV, Puto K, Allen PD. Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review. Value Health. 2013;16(5):872–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605.CrossRefPubMedGoogle Scholar
  7. 7.
    Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in management of prostate cancer. Onco Targets Ther. 2016;9:763–74.CrossRefGoogle Scholar
  8. 8.
    National Comprehensive Cancer Network. NCCN guidelines for patients with prostate cancer. Version 1.2016. National Comprehensive Cancer Network, Fort Washington, PA, U.S., 2016.Google Scholar
  9. 9.
    James ND, De Bono JS, Spears MR, Clarke N, Mason MD, Dearnaley DP, et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). J Clin Oncol. 2017;35:suppl. abstr LBA5003.Google Scholar
  10. 10.
    Fizazi K, Tran N, Fein LE, Matsubara N, Antolín AR, Alekseev BY, et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. J Clin Oncol. 2017;35:suppl. abstr LBA3.Google Scholar
  11. 11.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.CrossRefPubMedGoogle Scholar
  13. 13.
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-savings analysis of AR-V7 Testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide. Prostate. 2016;76(16):1484–90.CrossRefPubMedGoogle Scholar
  15. 15.
    Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy. A systematic review of randomised trials. Clin Oncol. 2003;15(6):345–52.CrossRefGoogle Scholar
  16. 16.
    Norum J, Traasdahl ER, Totth A, Nieder C, Olsen JA. Health economics and radium-223 (Xofigo®) in the treatment of metastatic castration-resistant prostate cancer (mCRPC): a case history and a systematic review of the literature. Glob J Health Sci. 2015;8(4):1–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Swedish National Board for Health and Welfare. Health economic data for the national guidelines for prostate cancer 2014. Stockholm: Swedish National Board for Health and Welfare; 2014.Google Scholar
  18. 18.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, et al. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017;20(2):121–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Ramaekers BL, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, et al. Abiraterone acetate for the treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer: an evidence review group perspective of an NICE single technology appraisal. Pharmacoeconomics. 2017;35(2):191–202.CrossRefPubMedGoogle Scholar
  21. 21.
    James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, et al. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technol Assess. 2016;20(53):1–288.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU Int. 2017;119(4):522–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Collinson L, Kvizhinadze G, Nair N, McLeod M, Blakely T. Economic evaluation of single-fraction versus multiple-fraction palliative radiotherapy for painful bone metastases in breast, lung and prostate cancer. J Med Imaging Radiat Oncol. 2016;60(5):650–60.CrossRefPubMedGoogle Scholar
  24. 24.
    Zheng HR, Wen F, Wu YF, Wheeler JR, Li Q. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective. Eur J Cancer Care. 2016. doi: 10.1111/ecc.12505.Google Scholar
  25. 25.
    Pilon D, Queener M, Lefebvre P, Ellis LA. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. J Med Econ. 2016;19(8):777–84.CrossRefPubMedGoogle Scholar
  26. 26.
    Bui CN, O’Day K, Flanders S, Oestreicher N, Francis P, Posta L, et al. Budget impact of enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2016;22(2):163–70.CrossRefPubMedGoogle Scholar
  27. 27.
    McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, et al. The clinical and economic impacts of skeletal-related events among Medicare enrollees with prostate cancer metastatic to bone. Oncologist. 2016;21(3):320–6.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Guirgis HM. The value of anticancer drugs in metastatic castrate-resistant prostate cancer: economic tools for the community oncologist. J Community Support Oncol. 2015;13(10):362–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Perrault L, Fradet V, Lauzon V, LeLorier J, Mitchell D, Habib M. Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: a population-based analysis. Can Urol Assoc J. 2015;9(9–10):307–14.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Robinson TJ, Dinan MA, Li Y, Lee WR, Reed SD. Longitudinal trends in costs of palliative radiation for metastatic prostate cancer. J Palliat Med. 2015;18(11):933–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Simpson EL, Davis S, Thokala P, Breeze PR, Bryden P, Wong R. Sipuleucel-T for the treatment of metastatic hormone-relapsed prostate cancer: a NICE single technology appraisal: an evidence review group perspective. Pharmacoeconomics. 2015;33(11):1187–94.CrossRefPubMedGoogle Scholar
  32. 32.
    Nickman NA, Ye X, Gaffney DK, Barney RB, Biskupiak JE, Okano GJ, et al. Cost of palliative external beam radiotherapy (EBRT) use for bone metastases secondary to prostate cancer. J Community Support Oncol. 2015;13(3):95–103.CrossRefPubMedGoogle Scholar
  33. 33.
    Torvinen S, Färkkilä N, Roine RP, Sintonen H, Saarto T, Taari K. Costs in different states of prostate cancer. Acta Oncol. 2016;55(1):30–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Gong CL, Hay JW. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Cancer Netw. 2014;12(10):1417–25.CrossRefGoogle Scholar
  35. 35.
    Seal B, Sullivan SD, Ramsey SD, Asche CV, Shermock K, Sarma S, et al. Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. Appl Health Econ Health Policy. 2014;12(5):547–57.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Dragomir A, Dinea D, Vanhuyse M, Cury FL, Aprikian AG. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Serv Res. 2014;14:252.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lee D, Porter J, Gladwell D, Brereton N, Nielsen SK. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom. J Med Econ. 2014;17(4):233–47.CrossRefPubMedGoogle Scholar
  38. 38.
    Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. Pharmacoeconomics. 2014;32(2):173–91.CrossRefPubMedGoogle Scholar
  39. 39.
    Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, et al. New therapeutic options in metastatic castration-resistant prostate cancer: can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Pract. 2014;20(6):417–25.CrossRefPubMedGoogle Scholar
  40. 40.
    Sorensen S, Ellis L, Wu Y, Hutchins V, Linnehan JE, Senbetta M. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Manag Care Pharm. 2013;19(9):799–808.PubMedGoogle Scholar
  41. 41.
    Krahn MD, Bremner KE, Zagorski B, Alibhai SM, Chen W, Tomlinson G, et al. Health care costs for state transition models in prostate cancer. Med Decis Mak. 2014;34(3):366–78.CrossRefGoogle Scholar
  42. 42.
    Zhong L, Pon V, Srinivas S, Nguyen N, Frear M, Kwon S, et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS One. 2013;8(5):e64275.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kearns B, Lloyd Jones M, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(6):479–88.CrossRefPubMedGoogle Scholar
  44. 44.
    Hagiwara M, Delea TE, Saville MW, Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16(1):23–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J Med Econ. 2013;16(1):19–29.CrossRefPubMedGoogle Scholar
  46. 46.
    Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ. 2012;15(5):836–43.CrossRefPubMedGoogle Scholar
  47. 47.
    Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2012;15(4):712–23.CrossRefPubMedGoogle Scholar
  48. 48.
    Lu L, Peters J, Roome C, Stein K. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 2012;109(8):1183–92.CrossRefPubMedGoogle Scholar
  49. 49.
    Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41(1):32–44.CrossRefPubMedGoogle Scholar
  50. 50.
    Statistics Canada. Canadian cancer statistics 2012. Toronto: Canadian Cancer Society; 2012.Google Scholar
  51. 51.
    Rencz F, Brodszky V, Varga P, Gajdácsi J, Nyirády P, Gulácsi L. The economic burden of prostate cancer. A systematic literature overview of registry-based studies. Orv Hetil. 2014;155(13):509–20.CrossRefPubMedGoogle Scholar
  52. 52.
    Rutter CE, Yu JB, Wilson LD, Park HS. Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys. 2015;91(3):548–55.CrossRefPubMedGoogle Scholar
  53. 53.
    Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007;11(12):1–128.CrossRefPubMedGoogle Scholar
  54. 54.
    Guirgis HM. Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? J Oncol Pract. 2012;8(4):224–8.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Zhang W, Islam N, Ma C, Anis AH. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics. 2015;33(4):327–40.CrossRefPubMedGoogle Scholar
  56. 56.
    Ghatnekar O, Nørgaard K, Skaltsa K. PCN191—results and implications of using a new eq-5d value set for cost-utility analyses in Sweden. An application using enzalutamide (Xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC). Value Health. 2014;17(7):A648.CrossRefPubMedGoogle Scholar
  57. 57.
    Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.CrossRefPubMedGoogle Scholar
  58. 58.
    Burström K, Sun S, Gerdtham UG, Henriksson M, Johannesson M, Levin LÅ, et al. Swedish experience-based value sets for EQ-5D health states. Qual Life Res. 2014;23(2):431–42.CrossRefPubMedGoogle Scholar
  59. 59.
    Kuykendal AR, Hendrix LH, Salloum RG, Godley PA, Chen RC. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the Medicare population and cost implications. Ann Oncol. 2013;24(5):1338–43.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of SurgeryFinnmark Hospital TrustHammerfestNorway
  2. 2.Department of Clinical Medicine, Faculty of Health ScienceUiT-The Arctic University of NorwayTromsøNorway
  3. 3.Department of Oncology and Palliative MedicineNordland HospitalBodøNorway

Personalised recommendations